{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:38:52Z","timestamp":1785526732879,"version":"3.56.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To define the diagnostic yield and anatomical distribution of [\u00b9\u2078F]prostate-specific membrane antigen (PSMA)-1007 positron emission tomography\/computed tomography (PET\/CT) in post-radical-prostatectomy biochemical recurrence (BCR) and to establish prostate-specific antigen (PSA)-stratified performance benchmarks, independent predictors of PET positivity, and clinical utility for PSMA-guided metastasis-directed therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-centre retrospective cohort of 245 consecutive BCR patients (PSA \u2265 0.2\u2009ng\/mL) who underwent uniform [\u00b9\u2078F]PSMA-1007 PET\/CT (90\u2009\u00b1\u200910\u2009min post-injection; molar activity &gt; 30 GBq \u00b5mol\u207b\u00b9) between June 2022 and November 2025 was analysed. Detection rates were correlated with PSA strata, and independent predictors of PET positivity were identified via multivariable logistic regression. Lesion location was verified by histology, targeted therapy response, or unequivocal imaging follow-up. Inter-observer agreement for image interpretation was quantified using Cohen\u2019s kappa,<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At median PSA 0.9\u2009ng\/mL (interquartile range 0.5\u20132.1), 184\/245 patients (75.1%, 95% CI: 69.3\u201380.3%) exhibited \u2265 1 [\u00b9\u2078F]PSMA-1007-avid lesion. Detection rates increased with PSA: 56.5% (0.2\u20130.5\u2009ng\/mL) to 90.5% (\u2265 1.5\u2009ng\/mL). Independent predictors of PET positivity were serum PSA (OR = 2.87), ISUP grade (OR = 1.63), and PSA doubling time (OR = 0.72) (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01). In 132 verified cases, a \u201cpelvic-first\u201d pattern was observed: isolated prostatic fossa (34.8%), isolated nodal (38.6%), isolated osseous (20.4%), and multi-region disease (6.1%). Median SUVmax was comparable across lesion types (\u2248 17.5;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.63), with excellent inter-observer agreement (Cohen\u2019s \u03ba = 0.86 for positivity, 0.82 for localization; both\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>[\u00b9\u2078F]PSMA-1007 PET\/CT delivers high, PSA-dependent detection efficiency even at PSA &lt; 0.5\u2009ng\/mL, with excellent inter-observer reliability. Serum PSA, ISUP grade, and PSA doubling time independently predict PET positivity, and the modality accurately maps predominantly pelvic, oligometastatic recurrences suitable for focal salvage therapy. These data support its utility as a first-line imaging tool for post-prostatectomy BCR staging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349397","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:34:41Z","timestamp":1778780081000},"page":"e0349397","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["[\u00b9\u2078F]PSMA-1007 PET\/CT in biochemical recurrence after radical prostatectomy: A single-center experience of detection rate and lesion distribution"],"prefix":"10.1371","volume":"21","author":[{"given":"Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3487-5795","authenticated-orcid":true,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"pone.0349397.ref001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-021-00249-2","article-title":"Prostate cancer","volume":"7","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0349397.ref002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"JL Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"pone.0349397.ref003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"N Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"27","key":"pone.0349397.ref004","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1080\/14796694.2025.2577633","article-title":"Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)","volume":"21","author":"AK Morgans","year":"2025","journal-title":"Future Oncol"},{"key":"pone.0349397.ref005","doi-asserted-by":"crossref","first-page":"1758835919876828","DOI":"10.1177\/1758835919876828","article-title":"Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?","volume":"11","author":"R Alipour","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"pone.0349397.ref006","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"J Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0349397.ref007","doi-asserted-by":"crossref","first-page":"612157","DOI":"10.3389\/fonc.2021.612157","article-title":"A pilot study of 18F-DCFPyL PET\/CT or PET\/MRI and ultrasound fusion targeted prostate biopsy for intra-prostatic PET-positive lesions","volume":"11","author":"Y Liu","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0349397.ref008","article-title":"Preclinical evaluation and first-in-human study of 68Ga- and Al18F-labeled PSMA\/FAP bispecific tracers for prostate cancer imaging","author":"X Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0349397.ref009","doi-asserted-by":"crossref","first-page":"3502389","DOI":"10.1155\/2021\/3502389","article-title":"18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis","volume":"2021","author":"M Ferrari","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"pone.0349397.ref010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"JR Landis","year":"1977","journal-title":"Biometrics"},{"issue":"1","key":"pone.0349397.ref011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","author":"PJL De Visschere","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"pone.0349397.ref012","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective evaluation of PSMA-targeted 18F-DCFPyL PET\/CT in men with biochemical failure after radical prostatectomy for prostate cancer","volume":"61","author":"SP Rowe","year":"2020","journal-title":"J Nucl Med"},{"key":"pone.0349397.ref013","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1007\/s00259-023-06355-5","article-title":"Total-body [68 Ga]Ga-PSMA-11 PET\/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"50","author":"Y Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"pone.0349397.ref014","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.adro.2019.09.004","article-title":"Dosimetric evaluation of PSMA PET-delineated dominant intraprostatic lesion simultaneous infield boosts","volume":"5","author":"CD Goodman","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"18","key":"pone.0349397.ref015","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.3390\/cancers15184589","article-title":"Predictors of PSMA PET positivity: analysis in a selected cohort of biochemical recurrence prostate cancer patients after radical prostatectomy","volume":"15","author":"P Mapelli","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"pone.0349397.ref016","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2214\/AJR.14.13766","article-title":"Evaluation of posttreatment follow-up of patients with prostate cancer relative to the american college of radiology\u2019s appropriateness criteria","volume":"205","author":"JS McDonald","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"10305","key":"pone.0349397.ref017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"S Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"pone.0349397.ref018","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.juro.2018.01.033","article-title":"Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms","volume":"199","author":"HJ Chalfin","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"pone.0349397.ref019","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study)","volume":"76","author":"TBL Lam","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0349397.ref020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2017.10.022","article-title":"Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET","volume":"126","author":"K Byrne","year":"2018","journal-title":"Radiother Oncol"},{"issue":"6","key":"pone.0349397.ref021","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"S Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"pone.0349397.ref022","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bju.16872","article-title":"Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer","volume":"136","author":"J Carll","year":"2025","journal-title":"BJU Int"},{"key":"pone.0349397.ref023","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer","volume":"64","author":"R Seifert","year":"2023","journal-title":"J Nucl Med"},{"issue":"8","key":"pone.0349397.ref024","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity","volume":"62","author":"M Kroenke","year":"2021","journal-title":"J Nucl Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:34:45Z","timestamp":1778780085000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349397"}},"subtitle":[],"editor":[{"given":"Alessandra","family":"Castelluccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349397","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}